TriSalus Life Sciences, Inc./$TLSI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About TriSalus Life Sciences, Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
Ticker
$TLSI
Sector
Primary listing
Employees
110
Headquarters
Website
TLSI Metrics
BasicAdvanced
$138M
-
-$1.14
0.50
-
Price and volume
Market cap
$138M
Beta
0.5
52-week high
$5.88
52-week low
$3.42
Average daily volume
59K
Financial strength
Current ratio
2.135
Quick ratio
1.57
Long term debt to equity
-96.008
Total debt to equity
-96.351
Interest coverage (TTM)
-7.41%
Profitability
EBITDA (TTM)
-31.081
Gross margin (TTM)
85.60%
Net profit margin (TTM)
-84.67%
Operating margin (TTM)
-99.01%
Effective tax rate (TTM)
-0.03%
Revenue per employee (TTM)
$290,000
Management effectiveness
Return on assets (TTM)
-85.52%
Return on equity (TTM)
78.55%
Valuation
Price to revenue (TTM)
3.024
Price to book
-3.43
Price to tangible book (TTM)
-3.43
Price to free cash flow (TTM)
-2.738
Free cash flow yield (TTM)
-36.53%
Free cash flow per share (TTM)
-1.333
Growth
Revenue change (TTM)
46.20%
Earnings per share change (TTM)
-81.38%
TLSI News
AllArticlesVideos
TriSalus Life Sciences Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock
Business Wire·3 weeks ago
TriSalus Life Sciences Announces Commencement of Exchange Offer and Consent Solicitation Relating to Series A Convertible Preferred Stock to Streamline Capital Structure
Business Wire·2 months ago
TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for TriSalus Life Sciences, Inc. stock?
TriSalus Life Sciences, Inc. (TLSI) has a market cap of $138M as of August 15, 2025.
What is the P/E ratio for TriSalus Life Sciences, Inc. stock?
The price to earnings (P/E) ratio for TriSalus Life Sciences, Inc. (TLSI) stock is 0 as of August 15, 2025.
Does TriSalus Life Sciences, Inc. stock pay dividends?
No, TriSalus Life Sciences, Inc. (TLSI) stock does not pay dividends to its shareholders as of August 15, 2025.
When is the next TriSalus Life Sciences, Inc. dividend payment date?
TriSalus Life Sciences, Inc. (TLSI) stock does not pay dividends to its shareholders.
What is the beta indicator for TriSalus Life Sciences, Inc.?
TriSalus Life Sciences, Inc. (TLSI) has a beta rating of 0.5. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.